Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed
cancers. Diagnostic challenges are deeply related to the development of personalized …

Abstract Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-
mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine …

Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …

Abstract EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC)
patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …